Prospects for development of a vaccine to prevent and control vaginal candidiasis.
Prospects for development of a vaccine to prevent and control vaginal candidiasis.
复制标题
DOI：
10.1007/s11908-010-0143-y
复制
发表时间：
2011-02-01
影响因子：
3.1
通讯作者：
Cutler, Jim E
中科院分区：
文献类型：
--
作者：
Fidel, Paul L Jr;Cutler, Jim E
针对复发性外阴阴道念珠菌病（RVVC）的疫苗将使大量患有这种衰弱综合征的妇女受益。到目前为止，已经测试了几种抗原制剂，结果一般。在这篇文章中，我们回顾了文献中报道的最新疫苗研究。候选物是与人类相容性佐剂一起施用的β-葡聚糖缀合物。在小鼠阴道炎模型中的结果也是适度的保护。然而，该研究包括活体动物成像以量化真菌负荷;用携带编码糖磷脂酰肌醇（GPI）连接的细胞壁蛋白和荧光素酶的基因的念珠菌菌株对动物进行攻击。真菌负荷表示为底物施用后的光子。保护作用似乎由β-葡聚糖抗体介导。虽然观察到适度的保护，但成像系统的可变性小于阴道灌洗液的半定量平板计数。尽管在评估保护方面取得了这些进展，但值得临床试验的RVVC候选疫苗仍然难以捉摸。
A vaccine against recurrent vulvovaginal candidiasis (RVVC) would benefit a large number of women who suffer from this debilitating syndrome. To date, several antigen formulations have been tested with modest results. In this article, we review the latest vaccine study reported in the literature. The candidate is a beta-glucan conjugate administered with a human compatible adjuvant. Results in a mouse model of vaginitis were again modest for protection. However, the study included live animal imaging to quantify fungal burden; animals were challenged with a Candida strain carrying a gene encoding a glycophosphatidylinositol (GPI)-linked cell wall protein and luciferase. Fungal burden was expressed as photons following substrate administration. Protection appeared to be mediated by beta-glucan antibodies. Although modest protection was observed, the imaging system was less variable than semi-quantitative plate counts of vaginal lavage fluid. Despite these advances in evaluating protection, a vaccine candidate against RVVC worthy of clinical testing remains elusive.